Safety and Immune Response to Recombinant Live-Attenuated Influenza H2N2 Virus Vaccine [clinicaltrials:NCT00722774]

Bio2RDF uri

Safety and Immune Response to Recombinant Live-Attenuated Influenza H2N2 Virus Vaccine [clinicaltrials:NCT00722774]

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

http://bio2rdf.org/clinicaltrials:NCT00722774

Bio2RDF identifier

NCT00722774

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00722774

http://www.w3.org/2001/XMLSchema#string

brief summary [clinicaltrials_vocabulary:brief-summary]

In the 20th century, in ...... influenza vaccine candidate.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Safety and Immune Response to Recombinant Live-Attenuated Influenza H2N2 Virus Vaccine

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Frequency of vaccine-related reactogenicity events and other adverse events Throughout study [clinicaltrials_resource:4dde3a29308908d32ca7b577d0ee5c1f]

Frequency of vaccine-related reactogenicity events and other adverse events Throughout study [clinicaltrials_resource:6a1d08cd2b86d7d9af7c09bd3dcb9030]

Frequency of vaccine-related reactogenicity events and other adverse events Throughout study [clinicaltrials_resource:b58d975efe4cece1591ef64347c06dc1]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Frequency of vaccine-related reactogenicity events and other adverse events Throughout study [clinicaltrials_resource:03bef600fc3b21a99232ebd1ba16584a]

Frequency of vaccine-related reactogenicity events and other adverse events Throughout study [clinicaltrials_resource:1ebef3889b6fa79d3d34ca6014388690]

Frequency of vaccine-related reactogenicity events and other adverse events Throughout study [clinicaltrials_resource:bcee6b8f3557f6b12aa39bce260a9f2c]

Frequency of vaccine-related reactogenicity events and other adverse events Throughout study [clinicaltrials_resource:fa5fe5e1f406d26f9a34beb1d9b0440c]

collaborator [clinicaltrials_vocabulary:collaborator]

National Institute of Allergy and Infectious Diseases (NIAID) [clinicaltrials_resource:d9a74aeb9c0d0448f38e08189395de72]

condition [clinicaltrials_vocabulary:condition]

Influenza [clinicaltrials_resource:5dc1031d142288171b361516700acc0a]

Virus Diseases [clinicaltrials_resource:a6f64ece6752177a842af57055655ecd]

condition browse [clinicaltrials_vocabulary:condition-browse]

Influenza, Human [clinicaltrials_resource:6327780a0a7cb5ca9e7487cedb62615f]

Virus Diseases [clinicaltrials_resource:a6f64ece6752177a842af57055655ecd]

condition mesh [clinicaltrials_vocabulary:condition-mesh]

Influenza, Human [clinicaltrials_resource:6327780a0a7cb5ca9e7487cedb62615f]

Virus Diseases [clinicaltrials_resource:a6f64ece6752177a842af57055655ecd]

country [clinicaltrials_vocabulary:country]

United States [clinicaltrials_resource:f253efe302d32ab264a76e0ce65be769]

detailed description [clinicaltrials_vocabulary:detailed-description]

H2N2 influenza viruses ...... and interim medical history.

http://www.w3.org/2001/XMLSchema#string

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00722774 [clinicaltrials_resource:13d9c53e94edd4f912688fe2e60f21aa]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2008-07-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

H2N2 1960 AA ca recombinant vaccine [clinicaltrials_resource:f10bcf21d270c2a7d1dde043948ccfa2]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

Yes

http://www.w3.org/2001/XMLSchema#string

is section 801 [clinicaltrials_vocabulary:is-section-801]

http://www.w3.org/2001/XMLSchema#string

keyword [clinicaltrials_vocabulary:keyword]

Influenza

http://www.w3.org/2001/XMLSchema#string

Vaccine

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2008-11-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

National Institute of Allergy and Infectious Diseases (NIAID) [clinicaltrials_resource:d9a74aeb9c0d0448f38e08189395de72]

location [clinicaltrials_vocabulary:location]

Johns Hopkins Bayview Medical Center, CIR Unit at the Mason F Lord Building [clinicaltrials_resource:5698ea38391fef2be413d29c555a4c97]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00722774

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

Phase I Inpatient Study of the ...... ion in the Event of a Pandemic

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

CIR 247

http://www.w3.org/2001/XMLSchema#string

overall official [clinicaltrials_vocabulary:overall-official]

Kawsar Talaat, MD [clinicaltrials_resource:28a0ed2842efa65c28cabb1f5dd9f80f]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

United States: Food and Drug Administration [clinicaltrials_resource:965595316c5ae1a4521a298d475eb908]

phase [clinicaltrials_vocabulary:phase]

Phase 1 [clinicaltrials_resource:ee4650e51426c7487977eeea8e7e6850]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2008-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

reference [clinicaltrials_vocabulary:reference]

18550873 [pubmed:18550873]

18582523 [pubmed:18582523]

18618064 [pubmed:18618064]

responsible party [clinicaltrials_vocabulary:responsible-party]

Kawsar Talaat, MD, Johns Hopkins Bloomberg School of Public Health [clinicaltrials_resource:784f9372412086d950ba829c1cab7a76]

source [clinicaltrials_vocabulary:source]

National Institute of Allergy and Infectious Diseases (NIAID) [clinicaltrials_resource:d9a74aeb9c0d0448f38e08189395de72]

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00722774 study design [clinicaltrials_resource:f1192d9eeab6d37b4345f39d95d7ee7d]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00722774

verification date [clinicaltrials_vocabulary:verification-date]

2008-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00722774

http://www.w3.org/2001/XMLSchema#string

title

Safety and Immune Response to Recombinant Live-Attenuated Influenza H2N2 Virus Vaccine

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

Safety and Immune Response to ...... e [clinicaltrials:NCT00722774]

@en